Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upanovimab
- Development stage
- Phase 3
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Upanovimab (SCTA01) is a humanized monoclonal antibody directed against the spike (S) protein of SARS-CoV-2, developed as a neutralizing antibody therapy for COVID-19. It binds the viral spike protein with high specificity and affinity, blocking interaction with the ACE2 receptor and thereby preventing viral entry into host cells and subsequent infection of respiratory tissues.[4][10] Upanovimab has been developed by Sinocelltech Group for treatment of COVID-19, with clinical development in Phase II/III programs in high-risk outpatients and hospitalized patients with COVID-19.[7][16]
- Other names
- anti-SARS-CoV-2 monoclonal antibodyanti-SARS-CoV2 monoclonal antibodyanti-SARS-CoV 2 monoclonal antibodyrecombinant humanized anti-SARS-CoV-2 monoclonal antibody
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on upanovimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upanovimab.